Jump To Slide... How to Properly Use the 'Jump to Slide' Feature 1 - Case Study 1 2 - Case Study 1 cont’d 3 - Overview 4 - Inter-Individual Variability in Drug Response 5 - Normal and Slow Metabolizers 6 - Slow Metabolizers-Prevalence 7 - Genetic Polymorphism-Autosomal Recessive Inheritance 8 - Pharmacogenetics 9 - Pharmacogenetics-History of the Field 10 - Drug Metabolism-Polymorphisms of Phase I and Phase II Reactions 11 - Drug Metabolism-Normal Metabolizers 12 - Drug Metabolism-Slow Metabolizers 13 - Isoniazid 14 - Isoniazid-Normal Metabolizers 15 - Isoniazid-Slow Metabolizers 16 - Isoniazid­Induced Hepatitis 17 - Isoniazid-Clinical Consequences in Slow Metabolizers 18 - Drugs That Undergo Polymorphic N-Acetylation 19 - Case Study 2 20 - Hydralazine 21 - Hydralazine-Metabolism 22 - Hydralazine-Slow Metabolizers 23 - Hydralazine-A Liver Study 24 - Hydralazine-Clinical Consequences in Slow Metabolizers 25 - Hydralazine-Induced SLE 26 - Case Study 3 27 - Mephenytoin 28 - Mephenytoin-Normal Metabolizers 29 - Mephenytoin-Slow Metabolizers 30 - Mephenytoin-A Population Study 31 - Mephenytoin-Clinical Consequences in Slow Metabolizers 32 - Mephenytoin-Drug Interactions in Slow Metabolizers 33 - Case Study 4 34 - Second-Generation Antihistamines 35 - Desloratadine 36 - Desloratadine-Metabolism 37 - Desloratadine-Slow Metabolizers 38 - Desloratadine-Slow Metabolizers Have a 6-Fold Increase in Bioavailability 39 - Desloratadine-Slow Metabolizers by Ethnicity 40 - Desloratadine-Slow Metabolizers 41 - Desloratadine-Adverse Events 42 - Drug-Related Adverse Events 43 - Genetic Polymorphisms-Clinical Relevance 44 - Genetic Polymorphisms-Implications for Drug Development 45 - Summary 46 - Thank You